Documentos de Calpena A.C. | REDI

Regresar

Mostrando 5 resultados de: 5

Filtros aplicados

Año de Publicación: "2018"

Subtipo de publicación

Publisher

CNS and Neurological Disorders - Drug Targets(1)

Journal of Nanobiotechnology(1)

Nanomedicine: Nanotechnology, Biology, and Medicine(1)

Área temáticas

Enfermedades(5)

Farmacología y terapéutica(5)

Medicina y salud(3)

Fisiología humana(1)

Ginecología, obstetricia, pediatría, geriatría(1)

Área de conocimiento

Farmacología(5)

Nanopartícula(2)

Descubrimiento de fármacos(1)

Origen

Palabras Claves

Nanoparticles(3)

Alzheimer's disease(2)

APPswe/PS1dE9 mice(1)

Comparative study of Ex Vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer's disease

Abstract: Pioglitazone has been reported in the literature to have a substantial role in the improvement of ov

Palabras claves:

Alzheimer's disease, Nanoparticles, Pioglitazone, PLGA-PEG, Transmucosal permeations

Calpena A.C., Espina M., García M.L., Halbaut L., Lupe Carolina Espinoza, Silva-Abreu M.

Development of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: In vitro and Ex vivo characterization

Abstract: Background: Donepezil (DPZ) is widely prescribed as a specific and reversible acetylcholinesterase i

Palabras claves:

Alzheimer’s disease, Delivery systems, Donepezil, Intranasal route, Microemulsion, permeation

Calpena A.C., Clares-Naveros B., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Vacacela M.

Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy

Abstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. Epigallocate

Palabras claves:

Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticles

Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.

Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: In vitro and in vivo characterization

Abstract: Background: Memantine, drug approved for moderate to severe Alzheimer's disease, has not shown to be

Palabras claves:

Alzheimer's disease, APPswe/PS1dE9 mice, astrocytes, BEnd.3, Brain targeting, Memantine, Nanoparticles, β-Amyloid plaques

Antoni Camins, Calpena A.C., Cano A., Carmona N., Egea M.A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Silva A.M., Souto E.M.B.

Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma

Abstract: Glaucoma is a multifactorial neurodegenerative disease associated with retinal ganglion cells (RGC)

Palabras claves:

drug delivery, glaucoma, Memantine, Nanoparticles, PLGA-PEG

Antoni Camins, Calpena A.C., Cordeiro M.F., Davis B.M., Egea M.A., Espina M., Ettcheto M., García M.L., Guo L., Ravindran N., Sanchez-Lopez E., Silva A.M., Souto E.M.B.